Pfizer to sell its Upjohn business to Mylan Pharma for Rs 180.48
Pfizer Ltd said in a regulatory filing that the company has entered into a business transfer agreement with Mylan Pharmaceuticals to transfer certain predominantly off-patent branded and generic established drugs (Upjohn business) to Mylan for Rs 180.48 crore.
The idea for transfer is supported by evaluation reports issued by two independent assessors, it added.
“The Upjohn business comprises six brands including Lyrica, Viagra, Celebrex, Amlogard, Daxid and Dilantin. These will be transferred to Mylan along with associated business assets and liabilities,” the filing said.
The rationale for the transaction is that Pfizer Inc., USA announced on July 29, 2019 that it has entered into a definitive agreement to combine its Upjohn business – which includes off-patent branded and generic established drugs – Mylan N.V. With, thus a new global pharmaceutical company, Viatris Inc.
The global transaction was closed in November 2020.
As part of the global transaction, six brands currently marketed by Pfizer Limited in India, namely, Lyrica, Viagra, Celebrex, Amlogard, Daxid and Dilantin, will convert to Mylan Pharmaceuticals.
Pfizer Limited said that the transaction in India will be closed once regulatory approval is received.
(Only the title and image in this report may have been reworked by Business Standard staff; the rest of the content is generated automatically from a syndicated feed.)
</div><div style="background: #fee8dd; padding: 12px; border: dashed 1px black; margin-bottom: 20px;">
Business Standard has always worked hard to provide updated information and commentary on events that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering has further strengthened our resolve and commitment to these ideals. Even during these difficult times arising out of COVID-19, we are committed to keeping you informed and updated with relevant news, authoritative views and sharp comments on relevant issues.
However, we have a request.
As we grapple with the economic impact of the pandemic, we need your support even more so that we can continue to provide you with more quality content. Our subscription model has received an encouraging response from many of you who have subscribed to our online content. Subscribing to more of our online content can only help us achieve our goals of providing you with better and more relevant content. We believe in independent, unbiased and credible journalism. Your support through more subscriptions can help us practice the journalism we’re committed to.
support quality journalism and Subscribe to Business Standard.
this is an unedited and auto-generated supporting article of the syndicated news feed are actualy credit for owners of origin centers. intended only to inform and update you about Sakari naukri , result , UPSC , Exam Jobs etc. for Provides real or authentic news. also Original content may not have been modified or edited by nixatube team members.